An Alloantibody Recognizing the FVIII A1 Domain in a Patient with CRM Reduced Haemophilia A due to Deletion of a Large Portion of the A1 Domain DNA Sequence

Summary We report the development of a FVIII inhibitor in a patient with severe, cross reacting material reduced (CRMR) haemophilia A. The level of Factor VIII antigen (FVIII:Ag) measured by ELISA using anti- C2 monoclonal and alloantibodies was 1.9 U/dl. This baseline FVIII:Ag level was increased to 8.3 U/dl after administration of DDAVP. The anti-FVIII inhibitor titer was 2.9 Bethesda U/ml. DNA analysis showed a large deletion of the FVIII gene from exon 4 to 7, corresponding to amino acid residues 111-317 included within the A1 domain. The size of the gene deletion was approximately 28 kb. 5' and 3' breakpoints were identified by sequencing in intron 3 and intron 7, respectively. FVIII mRNA was detected in the patient’s peripheral lymphocytes and the deletion spanning exon 4 to 7 was confirmed at the RNA level. Immunoprecipitation experiments using 125I labeled A1, A2 and light chain demonstrated that the inhibitor reacted only with the 54 kDa A1 domain. The inhibitor activity was more than 95% neutralized by A1 domain polypeptide. Our findings suggest a close relationship between the inhibitor epitope and the specific gene deletion with regard to the pathogenesis of the inhibitor in this patient.

[1]  J. Vermylen,et al.  Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. , 1999, Blood.

[2]  P. Browett,et al.  A 20.7 kb Deletion within the Factor VIII Gene Associated with LINE-1 Element Insertion , 1998, Thrombosis and Haemostasis.

[3]  R. Kaufman,et al.  Differential Interaction of Coagulation Factor VIII and Factor V with Protein Chaperones Calnexin and Calreticulin* , 1998, The Journal of Biological Chemistry.

[4]  A. Thompson,et al.  Loss of tolerance to exogenous and endogenous factor VIII in a mild hemophilia A patient with an Arg593 to Cys mutation. , 1997, Blood.

[5]  M. Shima,et al.  Factor VIII gene analysis in Japanese CRM‐positive and CRM‐reduced haemophilia A patients by single‐strand conformation polymorphism , 1997, British journal of haematology.

[6]  J. T. ten Cate,et al.  The missense mutation Arg593 --> Cys is related to antibody formation in a patient with mild hemophilia A. , 1997, Blood.

[7]  M. Shima,et al.  Factor VIII Ise (R2159C) in a Patient with Mild Hemophilia A, an Abnormal Factor VIII with Retention of Function but Modification of C2 Epitopes , 1997, Thrombosis and Haemostasis.

[8]  Jerzy Jurka,et al.  Censor - a Program for Identification and Elimination of Repetitive Elements From DNA Sequences , 1996, Comput. Chem..

[9]  J. Oldenburg,et al.  Haemophilia A: Mutation Type Determines Risk of Inhibitor Formation , 1995, Thrombosis and Haemostasis.

[10]  F E Preston,et al.  Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. , 1995, Blood.

[11]  L. Hoyer,et al.  Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. , 1994, Seminars in hematology.

[12]  D. Scandella,et al.  A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. , 1993, Blood.

[13]  P. Fay,et al.  von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. , 1991, The Journal of biological chemistry.

[14]  C. Fulcher,et al.  Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. , 1989, Blood.

[15]  S. Dimauro,et al.  A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. , 1989, Science.

[16]  C. Fulcher,et al.  Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Houghten,et al.  Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. , 1988, The Journal of clinical investigation.

[18]  S. Antonarakis,et al.  Characterization of five partial deletions of the factor VIII gene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Vehar,et al.  Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. , 1986, Biochemistry.

[20]  J. Roberts,et al.  Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. J. Potter,et al.  Characterization of the polypeptide composition of human factor VIII:C and the nucleotide sequence and expression of the human kidney cDNA. , 1985, DNA.

[22]  B. Keyt,et al.  Structure of human factor VIII , 1984, Nature.

[23]  E. Chen,et al.  Characterization of the human factor VIII gene , 1984, Nature.

[24]  B. Keyt,et al.  Expression of active human factor VIII from recombinant DNA clones , 1984, Nature.

[25]  G. Knutson,et al.  Molecular cloning of a cDNA encoding human antihaemophilic factor , 1984, Nature.

[26]  L. Hoyer,et al.  Immunoradiometric measurement of the factor VIII procoagulant antigen. , 1978, The Journal of clinical investigation.

[27]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[28]  P. Mannucci,et al.  1-DEAMINO-8-D-ARGININE VASOPRESSIN: A NEW PHARMACOLOGICAL APPROACH TO THE MANAGEMENT OF HAEMOPHILIA AND VON WILLEBRAND'S DISEASE , 1977, The Lancet.

[29]  E. Southern.  Detection of specific sequences among DNA fragments separated by gel electrophoresis. , 1975, Journal of molecular biology.

[30]  R. Biggs,et al.  Two Types of Haemophilia (A+ and A−): A Study of 48 Cases , 1969, British journal of haematology.

[31]  J. Marchalonis.  An enzymic method for the trace iodination of immunoglobulins and other proteins. , 1969, The Biochemical journal.

[32]  L. Hoyer,et al.  Immunologic studies of antihemophilic factor (AHF, factor VIII): cross-reacting material in a genetic variant of hemophilia A. , 1968, Blood.

[33]  R. Hardisty,et al.  A One-stage Factor VIII (Antihaemophilic Globulin) Assay and its Use on Venous and Capillary Plasma , 1962, Thrombosis and Haemostasis.

[34]  Geoffrey Kemball-Cook,et al.  The Factor VIII Mutation Database on the World Wide Web: the haemophilia A mutation, search, test and resource site. HAMSTeRS update (version 3.0) , 1997, Nucleic Acids Res..

[35]  Voorberg,et al.  The missense mutation Arg 593-> cys is related to antibody formationin apatient with mild hemophilia , 1997 .

[36]  D. Green,et al.  A More Uniform Measurement of Factor VIII Inhibitors , 1975, Thrombosis and Haemostasis.